Polyp Biopsy Market Research Report – Global Forecast till 2030

Polyp Biopsy Market Research Report: Information by Type (Colonoscopy, Colposcopy-Directed Biopsy, Esophagogastroduodenoscopy and Laryngoscopy), Distribution Channel (Online Sales Channels, Retail Pharmacies), End User (Hospitals & Clinics, Diagnostic Centres and Academic & Research Organizations) - Forecast till 2030

ID: MRFR/MED/1141-HCR | 90 Pages | Published By Kinjoll Dey on March 2023         

Polyp Biopsy Market Speak to Analyst Request a Free Sample

Polyp Biopsy Market Overview

The Polyp biopsy market is expected to reach USD 2,347.2 Million by 2030 at 8.4% CAGR during the forecast period 2022-2030. Polyps are benign growths generated by aberrant cell division. They can, however, become malignant if left untreated. To summarise, it is critical to detect polyps to avert cancer. The biopsy is a common diagnostic procedure for this purpose. A sample of tissue from the polyp is extracted and studied under a microscope in this operation. With the use of a polyp biopsy, diseases such as non-small cell lung carcinoma, head and neck cancer, breast cancer, lymphomas, leukemia, and breast and liver cancer can be detected early. These are the five most frequent cancers that affect people all around the world. Cancers of the bowel, stomach, and liver are also common worldwide. As a result of the increased incidence of various tumors, the Polyp Biopsy Market Growth has grown.

Because of the adoption of western lifestyles and choices in economically developing countries, such as smoking, bad food, physical inactivity, and fewer childbirths, the future load is predicted to be considerably greater. The demand for early cancer diagnosis is expected to have an impact on the polyp biopsy market growth. In the diagnosis of solid and various cancers, polyp biopsy has been in high demand which has changed the polyp biopsy market outlook. According to WHO statistics, cancer is the world's second-biggest cause of death, with around 18 million new cases reported globally during the historic forecast period. In the next two decades, the number of new cases is predicted to increase by almost 70%. The global burden of cancer is anticipated to increase to 21.7 million new cases and 13 million cancer deaths by 2030, owing to population aging.

COVID Analysis

Since its first appearance in Wuhan, China, in December 2019, the coronavirus disease, caused by the novel severe acute respiratory syndrome coronavirus, has swiftly spread over the world, prompting the World Health Organization to designate it a pandemic. The rising number of patients requiring hospitalization necessitated the temporary conversion of entire hospitals into COVID-19 facilities and a significant redeployment of medical professionals to address the pandemic's continuous load. All elective operations should be canceled or postponed until the epidemiologic situation improves, to more effectively combat the pandemic and free up hospital resources.

This postponement of elective surgery and invasive diagnostic treatments will have a significant impact on patient quality of life, since some patients will present with more advanced disease, necessitating more difficult surgeries and poor surgical results. As a result, diagnostic and surgical procedures had to be altered to provide the bare minimum of care for non-urgent and non-oncologic patients, primarily through the use of personal protective equipment (PPE) and various physical barriers to reduce exposure to potentially viral-containing droplets and aerosol particles in the operating room. Some reports showed a new technique for removing cancer i.e. polyp biopsy in the office setting while also taking into account the safety precautions advised for ambulatory examinations.

Polyp Biopsy Market Dynamics


The polyp biopsy market share is expected to develop due to rising polyp occurrences, aging demographics, and the rising frequency of colorectal cancer. Furthermore, technical improvements in the field of biopsy are projected to propel the market. The market can be ascribed to the rising demand for Polyp Biopsy in Hospitals, Clinics, Diagnostic Centers, and Research Laboratories applications all over the world. Within the diagnostic sector, these diagnostics are gaining traction. The market is predicted to increase rapidly, with rising breast cancer occurrences being one of the main drivers during the market forecast.


Regulatory uncertainty and the risk of infection after biopsy are projected to limit market growth throughout the projection period. The most significant market constraint is the high cost of medications, as biopsy is far more expensive and the typical person cannot afford it. The market value of polyp biopsies is likely to be hampered by the FDA's strict approval standards for new treatments or medications, as well as a rise in demand for alternative treatment methods. Lack of awareness, particularly in developing nations, is projected to be a barrier for the polyp biopsy market outlook over the forecast period.

Biopsy-related technology breakthroughs are projected to drive market. Technological advancements and developments will give profitable opportunities for Global market participants during the forecast years. Polyp biopsies are growing more popular throughout the world's population. Healthcare capital expenditure installed base of various types of products for the polyp biopsy market, the impact of technology using lifeline curves, and changes in healthcare regulatory scenarios and their impact on the polyp biopsy market are all increasing as a result of technological advancements during the forecast period.

Polyp Biopsy Market Segment Overview

Based on the type, the global market has been segmented as follows:

  • Colonoscopy

  • Colposcopy-Directed Biopsy

  • Esophagogastroduodenoscopy

  • Laryngoscopy

Based on the distribution channel, the global market has been segmented as follows:

  • Online Sales Channels

  • Retail Pharmacies

  • Others

Based on the end-user, the global market has been segmented as follows:

  • Hospitals & Clinics

  • Diagnostic Centers

  • Academic & Research Organizations

Polyp Biopsy Market Regional Classification

Due to well-developed healthcare infrastructure and an increase in the creation of polyps in individuals, the Americas are expected to lead the polyp biopsy market.

The second-largest share of the market is predicted to be held by Europe. This can be ascribed to the region's robust healthcare sector and government backing.

China, Japan, India, Australia, South Korea, and the rest of Asia-Pacific make up the polyp biopsy market in Asia-Pacific. Because of the high frequency of polyps, rising healthcare expenditures, and increased market penetration, the area is expected to have the greatest CAGR during the forecast period. During the historic forecast period, the prevalence of polyps in mainland China was predicted to be around 23.9 percent.

Due to underdeveloped economies, severe government controls, and low per capita income in Africa, the Middle East, and Africa are expected to hold the smallest part of the market. Because of its strong healthcare infrastructure and the existence of economies like Saudi Arabia, Kuwait, and Dubai, the Middle East is expected to lead the industry.

Polyp Biopsy Market Competitive Landscape

Significant events, such as business combinations, joint ventures, achievements, new product innovations, or market activities, are organized by the leading key players to expand the market growth. The major players provide information such as company snapshots, financial position, recent developments, and other pertinent information. This helps the company flourish and this important personnel realize their objectives. The major key players of the global polyp biopsy market are as follows:

  • Cardinal Health, Inc.

  • Angiotech

  • Carefusion Corporation

  • R. Bard, Inc.

  • Hologic, Inc.

  • INRAD Inc.

  • NeoDynamics AB

  • Devicor Medical Products Inc.

  • Olympus

  • IZI Medical Products

  • DTR Medica

Recent Developments

IZI Medical Products, LLC, a major developer of medical devices used in interventional radiology and interventional oncology treatments, has launched the Quick-Core Auto Biopsy Systems for polyp biopsy. The Quick-Core Auto is a portable, fully automatic biopsy devices that enhances the dependability, precision, and quality of IZI's semi-automatic Quick-Core biopsy system.

NeoDynamics AB, a MedTech company focused to improve breast cancer diagnosis and treatment, has announced a collaboration with the Buckinghamshire Healthcare NHS Trust in London for their NeoNavia pulse biopsy device.

Polyp Biopsy Market Report Overview

The Polyp Biopsy Market detailed study will examine data changes and their impact on the market at a global level. It also examines the market's general growth and companies' ability to manage and maintain profit levels, which is critical for any investor looking to start or expand a business in the same sector. This report is broken down into numerous sections that address distinct aspects of the market. The Market's growth factors, drivers, restraints, and trends have all been studied using research approaches. The research identifies the region and market category that is likely to expand the fastest and dominate the industry.

Intended Audience

  • Medical device companies

  • Contract research organizations

  • Contract manufacturing organizations

  • Research and development organization

  • Academics and research institutes

Report Scope:

Report Attribute/Metric Details
  Market Size   2,347.2 Million
  CAGR   8.4%
  Base Year   2021
  Forecast Period   2022-2030
  Historical Data   2020
  Forecast Units   Value (USD Million)
  Report Coverage   Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
  Segments Covered   by Type, Distribution Channel
  Geographies Covered   North America, Europe, Asia-Pacific, and Rest of the World (RoW)
  Key Vendors   Cardinal Health, Inc., Angiotech, Carefusion Corporation, C.R. Bard, Inc., Hologic, Inc., INRAD Inc., Devicor Medical Products Inc., Olympus, and DTR Medica
  Key Market Opportunities   Growing geriatric populations, and increasing prevalence of colorectal cancer are projected to drive the market growth.
  Key Market Drivers   On the other hand, uncertain regulatory issues and biopsy-related risk of infections are expected to restrict the market growth during the forecast period.

Speak to Analyst Ask for Customization

Frequently Asked Questions (FAQ) :

Polyp biopsy market CAGR would be 8.4% during the forecast period.

The players in polyp biopsy report areAngiotech, INRAD Inc., Cardinal Health, Inc., Hologic, Inc., Carefusion Corporation, C.R. Bard, Inc., Olympus, Devicor Medical Products Inc., and DTR Medica.

The Americas would lead the polyp biopsy market.

Polyp biopsy market valuation would be USD 2,347.2 Million.

The distribution channels of polyp biopsy market report are online sales channel and retail pharmacies.